Afatinib Recruiting Phase 2 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02716311Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer
NCT02183883Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
NCT03157089Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
NCT02597946Afatinib in NSCLC With HER2 Mutation